Multi-analyte Blood Test Clinical Trial

Official title

Collection of Blood to Evaluate Epigenomics and Protein Biomarkers for the Detection of Hepatocellular Carcinoma

Overview

The objective of this study is the acquisition of whole blood samples and serum samples from participants with untreated Hepatocellular Carcinoma (HCC) and subjects undergoing Hepatocellular Carcinoma (HCC) surveillance. These samples will be used for research purposes to develop and validate the Helio multi-analyte blood test.

Detailed description

This study pertains to the collection of whole blood and serum specimens from participants undergoing Hepatocellular Carcinoma (HCC) surveillance. The participants will fall into two main groups, subjects diagnosed with HCC (HCC positive Group) or subjects without HCC (HCC negative Group).

The HCC negative Group will be further divided into two sub-groups based on whether the absence of HCC has been determined using CT or MRI procedures (Sub-group 1) or ultrasound (Sub-group 2). Only the participants in sub-group 2 will receive a confirmatory ultrasound approximately 6 months (between 5 to 9 months) after enrollment to confirm the absence of HCC (6-month visit). This additional imaging study is necessary due to the low sensitivity of abdominal ultrasound to detect HCC lesions.

Participants will be screened for eligibility to participate in the study based on their medical history and records. Participants with a recent confirmed Collection of Blood to Evaluate Epigenomics and Protein Biomarkers for the detection of Hepatocellular Carcinoma diagnosis of HCC (within 6 months of enrollment) may be enrolled in such way to ensure the cases are representative of the major liver disease etiologies in the surveillance population in the United States.

Specifically, the following causes of cirrhosis will be selected:

* Alcoholic steatohepatitis (ASH); * Hepatitis B virus (HBV); * Hepatitis C virus (HCV); * Non-alcoholic fatty liver disease (NAFLD); * Other genetic conditions that cause cirrhosis (i.e., hemochromatosis)

These blood samples will be used to perform various studies to determine the utility of selected DNA methylation and protein markers for the liver cancer diagnostic test.

Interventions

• Diagnostic test Multi-analyte Blood Test
  A clinical diagnostic test based upon the detection and quantification of DNA methylation markers in cell-free DNA (cfDNA) isolated from plasma and of tumor-specific proteins isolated from serum.

Primary outcome measures

• Independent performance measure of sensitivity and specificity of a multi-analyte blood test [Time frame: 1 - 9 months]

Secondary outcome measures (3)

• To investigate potential endogenous and exogenous interfering substances of a multi-analyte blood test [Time frame: 1 - 9 months]
• Ascertain Reference Range(s) [Time frame: 1 - 9 months]
• Ascertain Sample Stability [Time frame: 1 - 9 months]

Eligibility criteria

Inclusion criteria

• Age 18 years or older.
• Males and Females.
• Having cirrhosis or meeting the AASLD guidelines for HCC
• surveillance.
• Clinically diagnosed with HCC or negative for HCC following disease
• surveillance.
• HCC positive Group: Subject has a recent (within 6 months of enrollment) clinically diagnosed, untreated hepatocellular carcinoma as defined by at least one ≥1 cm lesion exhibiting arterial phase hyperenhancement in combination with washout appearance and/or capsule by 4 phase CT scan or multiphase contrast enhanced MRI or biopsy is positive for HCC.
• HCC negative Group: Non-cancer, at-risk subjects with chronic liver disease undergoing routine imaging surveillance for HCC, where the definitive lack of HCC within 3 months prior to enrollment has been verified by negative imaging, for HCC. No more than 200 subjects without cirrhosis can be enrolled in this group.
• Sub-Group 1 (approximately 450 subjects) - negative by CT or MRI (No lesion, LR-1 or LR-2)
• Sub-Group 2 (approximately 450 subjects) - negative by ultrasound

Exclusion criteria

• Subjects that are unwilling or unable to sign the Informed Consent Form will be excluded.
• Known cancer diagnosis of a cancer other than HCC within the past 5 years (with the exceptions of basal cell or squamous cell skin cancers).
• Chemotherapy and/or radiation therapy within 5 years prior to enrollment/sample collection.
• Prior or current treatment with sorafenib, regorafenib, or other treatment indicated for HCC.
• Prior treatment with a DNA methyltransferase inhibitor such as with Vidaza (azacitidine) or Dacogen (decitabine)
• Any HCC treatment prior to enrollment/blood sample collection (e.g., surgery, ablation, embolization, pharmacotherapy, radiotherapy, liver transplant or other treatment indicated for HCC).
• IV contrast (e.g., CT and MRI) within 1 day \[or 24 hours\] of blood collection.
• Less than 3 days between fine needle aspiration (FNA) of target pathology and blood collection.
• Less than 7 days between biopsy (other than FNA) of target pathology and blood collection.
• Any condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk.
• For HCC negative subjects, patients with a prior diagnosis of HCC are also excluded.
• Subjects that are pregnant will be exclude

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Study design

Observational model

Other

Study locations

United States · 7 centers

• Gastroenterology and Liver Institute — Escondido
• Providence Facey Medical Foundation — Mission Hills
• UF Hepatology Research at CTRB — Gainesville
• Guardian Angel Research Center — Tampa
• South Texas Research Institute — Edinburg
• Texas Gastro Research — El Paso
• Impact Research Institute — Waco

Identifiers

NCT: NCT05199259 · HELIO-2021-US-002

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗